Cheyenne, Wyoming, December 29, 2017: The Board of Directors of Argus Worldwide Corp (www.argusworldwide.com), a US portfolio management and investment firm, reported today on its corporate focus for fiscal 2018 and beyond.
The Company noted that its primary focus will be to raise additional investment capital to continue development programs on its Cyber Junky digital platform (www.cyberjunky.com) and recently acquired BioPharmcor BV generic drug business for men. Pending a successful round of funding through the end of Q2 2018, the Company is forecasting major advances 1) on product development activities in building out Cyber Junky as an innovative ‘one-stop’ aggregator of the most sought after digital utility applications to enhance the day to day digital experience for both personal and business requirements; and 2) in completing the development cycle of its BioPharmcor unit’s tadalafil, a generic drug for men experiencing Erectile Dysfunction syndrome (ED) and/or Benign Prostatic Hyperplasia (BPH).
A spokesman for Argus Worldwide Corp. points out “that both Cyber Junky and BioPharmcor BV will be participating in mega dollar global markets and the return on investment, if successful, can be hugely rewarding for the company and its stakeholders. We are excited about the tremendous potential that lies before us in both the IT and pharma sectors and on balance we are confident with the direction that our Company is taking in addressing its investment portfolio over both the short to long term.”
Argus Worldwide Corp. is a US corporation engaged in portfolio management and alternative investment strategies with its registered head office in Cheyenne, Wyoming, The Company has affiliated offices in Ottawa, Canada; Warsaw, Poland; and Amsterdam, The Netherlands. Shares of Argus Worldwide Corp. are traded on the US OTC Markets; Pink Current (symbol: ARGW).
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "will" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Corporation. The forward-looking information contained in this release is made as of the date hereof and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained here.
For more information contact:
Argus Worldwide Corp.
In North America: 1-613-731-5935 In Europe: +48-787-668-861